Charles M. Rudin

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

131h-index85.3kcitations1.7kworks4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(664), Lung Cancer Treatments and Mutations(618), Neuroendocrine Tumor Research Advances(189), Cancer Genomics and Diagnostics(186), Cancer Immunotherapy and Biomarkers(160)

Publications1.7k total

Analysis of <scp>SCLC</scp> subtype markers ( <scp>ASCL1</scp> , <scp>NEUROD1</scp> , <scp>POU2F3</scp> , <scp>YAP1</scp> ), <scp>DLL3</scp> , <scp>OTP,</scp> and <scp>TTF1</scp> in 300 lung carcinoids and enteropancreatic neuroendocrine tumours
Histopathology·2026Open Access
Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact
Journal of Thoracic Oncology·2026· 1 citedOpen Access
Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer
SSRN Electronic Journal·2026Open Access
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS
Lung Cancer·2025
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer
Nature Communications·2025· 2 citedOpen Access
Abstract A009: Defining and targeting L1CAM-driven metastasis progenitor cells in lung adenocarcinoma
Cancer Research·2025
Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2025Open Access
Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Table S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
2025Open Access
page 1 of 84Next →

Frequent Co-authors

Marc Ladanyi(11), Michael F. Berger(10), Natasha Rekhtman(10), John T. Poirier(10), Matthew D. Hellmann(9), Gregory J. Riely(8), Ai Ni(8), David B. Solit(7), Mark G. Kris(7), Jamie E. Chaft(6), Jedd D. Wolchok(6), Maria E. Arcila(6), Christine L. Hann(6), Alexander Drilon(6), Ahmet Zehir(5), Darragh Halpenny(5), Jennifer L. Sauter(5), Jennifer A. Low(5), Robert L. Yauch(5), Martin H. Voss(4)